Meet the Dividend King Stock That's Up 20% in 2026. Here's Why It Can Continue Outperforming the S&P 500 and Nasdaq-100 in the Second Half.

Colgate-Palmolive is up 20.4% YTD and is projected to grow 2026 net sales 2%–6% (organic 1%–4%), despite margins ticking down. The stock trades at ~25x forward earnings and yields 2.2%, but the article highlights resilience from a diversified brand/region mix, with Q1 2026 net sales up 8.4% YoY and Latin America/EMEA posting double-digit growth. Cash generation remains strong (TTM free cash flow per share at a record $4.66) alongside shareholder returns via an affordable, 63-year dividend-growth streak and a 10% share count reduction over the last decade.

Analysis

CL is being rewarded less for absolute growth than for the quality of that growth: the mix is less U.S.-consumer-sensitive than most staples, so earnings should hold up better if North America stays soft. That makes it a structural winner versus KMB, KVUE, and CLX in a choppy demand environment, but it also means the market is already paying up for resilience; at roughly 25x forward earnings, incremental upside depends on re-acceleration, not just defensiveness.

The second-order effect is that CL’s strength raises the bar for the rest of the category. If it keeps taking share through better execution and pet nutrition, weaker peers will likely defend volume with discounting, which can pressure margins more than topline and force shelf-space concessions at retailers. In a lower-inflation world, that backdrop actually helps cheaper names more than CL because their multiple expansion can come from easier comps, while CL has less room to rerate.

Contrarian view: the consensus is treating premium quality as a free option, but this is a bond-proxy stock with valuation risk. The near-term catalyst path is simple: if organic growth stays at the low end and margin drift persists, the premium can compress 10-15% quickly; if growth is revised up or margins inflect for two straight quarters, the multiple likely stays intact. Falsifiers are a guidance raise above current ranges, a sharper-than-expected margin recovery, or a durable acceleration in North America that proves this is not just an EM/FX story.

Key Decisions for Investors

• Do not chase CL after the run-up; wait for a 5-7% pullback or post-earnings weakness before adding.
• Relative-value trade: long CL / short KMB or KVUE on any strength, targeting 5-8% relative outperformance over 1-3 months if CL holds guidance and peers remain margin constrained.
• If already long staples, rotate capital from CLX or KMB into CL rather than adding gross exposure; this preserves defensiveness while improving earnings quality.
• Set a watch item on CL organic sales and North America trends; if organic growth falls below the low end of guidance or pet nutrition slows, trim immediately because the valuation premium can compress fast.